Profund Advisors LLC Grows Stock Holdings in Seagen Inc. (NASDAQ:SGEN)

Profund Advisors LLC grew its holdings in Seagen Inc. (NASDAQ:SGENFree Report) by 20.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,023 shares of the biotechnology company’s stock after acquiring an additional 3,209 shares during the period. Profund Advisors LLC’s holdings in Seagen were worth $4,036,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of SGEN. American Century Companies Inc. lifted its position in shares of Seagen by 18.4% during the 1st quarter. American Century Companies Inc. now owns 4,559 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 710 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Seagen by 5.8% during the 1st quarter. HighTower Advisors LLC now owns 1,538 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 84 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Seagen by 1,484.0% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,566 shares of the biotechnology company’s stock worth $370,000 after purchasing an additional 2,404 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Seagen during the 1st quarter worth $1,166,000. Finally, Yousif Capital Management LLC lifted its position in shares of Seagen by 5.8% during the 1st quarter. Yousif Capital Management LLC now owns 2,002 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 110 shares during the last quarter. 84.26% of the stock is owned by hedge funds and other institutional investors.

Seagen Price Performance

Shares of NASDAQ:SGEN remained flat at $228.74 on Friday. 86 shares of the stock were exchanged, compared to its average volume of 1,478,439. Seagen Inc. has a 1-year low of $123.77 and a 1-year high of $228.96. The business has a 50-day moving average price of $228.74 and a 200-day moving average price of $216.86. The company has a market cap of $42.93 billion, a PE ratio of -57.04 and a beta of 0.32.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. StockNews.com assumed coverage on shares of Seagen in a research report on Saturday, February 17th. They issued a “hold” rating for the company. TheStreet cut shares of Seagen from a “c-” rating to a “d+” rating in a research report on Friday, November 3rd. Ten investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $210.45.

View Our Latest Report on SGEN

About Seagen

(Free Report)

Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

Further Reading

Want to see what other hedge funds are holding SGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seagen Inc. (NASDAQ:SGENFree Report).

Institutional Ownership by Quarter for Seagen (NASDAQ:SGEN)

Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.